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INTRODUCTION
Sugammadex is a modified γ -cyclodextrin and is
a selective relaxant binding agent, which was spe-
cifically developed as a reversal agent for aminos-
teroid neuromuscular agents (1). Sugammadex has
been shown to provide rapid and dose-dependent
reversal of profound neuromuscular blockade in-
duced by high-dose rocuronium (1.0-1.2 mg/kg) in
adult surgical patients (2). Re-administration of ro-
curonium is not recommended soon after sugam-
madex administration. However, certain situations
may require immediate induction of neuromuscu-
lar blockade following sugammadex. We present a
case where rocuronium was unable to induce com-
plete muscle relaxation and spontaneous breathing
was controlled by volatile and intravenous anesthe-
sia.
CASE PRESENTATION
The patient was a 72-year old female, 150 cm,
43 kg, and American Society of Anesthesiologists
Physical Status II due to hypertension. The patient
underwent surgery for a right cerebral artery aneu-
rysm and was monitored with an ECG, pulse ox-
imetry, heart rate, mean arterial pressure, and body
temperature. Remifentanil (0.1 μg/kg/min), propo-
fol (50 mg), and rocuronium (50 mg) were used
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for induction of anesthesia.
Anesthesia was maintained by remifentanil (0.2-
0.5 μg/kg/min), sevoflurane (1%), and rocuronium
(10 mg i.v. every 90 minutes). Total operation time
was 230 minutes.
After the operation, sugammadex (400 mg) was
injected and spontaneous breathing returned imme-
diately. The patient became conscious, alert, and
orientated but was unable to move her left side.
Approximately 25 minutes after sugammadex ad-
ministration, immediate exploration of the surgical
site was decided. The patient was immediately hy-
perventilated to eliminate spontaneous breathing,
however, this was unsuccessful. As a result, the pa-
tient was then administered rocuronium (50 mg).
The patient continued to have spontaneous respi-
ration and a repeat dose of rocuronium (50 mg) was
injected and sevoflurane (2%) and remifentanil (0.5
μg/kg/min) were maintained to control breathing.
The total operation time for the second procedure
was 117 minutes and sugammadex (400 mg) was
administered at the conclusion of the surgery. The
patient again became conscious, alert, and orien-
tated without any palsy or hemiplegia and was ex-
tubated.
The patient’s remaining hospital course was un-
eventful and the patient was discharged.
DISCUSSION
Sugammadex has revolutionized post-operative
care as it is able to reverse neuromuscular block-
ade safely, rapidly, and efficiently. Investigators have
shown that 4.0 mg/kg dosing of sugammadex is
able to work in a dose-dependent manner and that
rocuronium (1.2 mg/kg) can be effectively reversed
in under 20 minutes (3). However, increasing the
dose of sugammadex can effectively decrease the
reversal time and hasten recover to less than 2 min-
utes (3). In this patient, by utilizing a high dose of
sugammadex the patient was able to quick recover
from deep neuromuscular block, therefore, quickly
identifying and addressing subsequent hemiplegia.
However, certain situations such as in this case,
immediate muscular relaxation may be necessary
following sugammadex administration. We show
that normal doses of rocuronium were unable to
induce muscular relaxation and that a second dose
plus sevoflurane and remifentanil were required in
order to obtain suppression of spontaneous respi-
ration.
Previous studies have shown that terminal elimi-
nation half-life of sugammadex is around 120 min-
utes (4) and that sugammadex requires nearly 24
hours to be excreted (5). Although an exact time
has not been established, it is expected that imme-
diately after sugammadex there may be a lag time
before rocuronium can be administered again. How-
ever, in cases where neuromuscular blockade is
necessary immediately after sugammadex admini-
stration, other neuromuscular blocking agents, in-
haled anesthetics and/or opioids can be utilized to
control respiration.
Theoretical calculations of the dose of rocuronium
required to provide adequate neuromuscular block
immediately after sugammadex (8 mg/kg) is esti-
mated at 2.25 mg/kg (6) and is affected by the du-
ration between the second rocuronium dose and
sugammadex (7). Furthermore, rocuronium (1.2
mg/kg) was able to induce neuromuscular block-
ade in healthy patients following sugammadex (4
mg/kg), although, onset of blockade was slower if
rocuronium was injected25 minutes after sugam-
madex (8). The patient in this case originally re-
ceived rocuronium (1.2 mg/kg) on induction and
then received 10 mg every 90 minutes to maintain
blockade. Sugammadex (9.3 mg/kg) was adminis-
tered at the conclusion of the procedure and the
patient was then administered rocuronium (1.2 mg/
kg2 doses) approximately 25 minutes later. By
utilizing the pharmacokinetic data for sugammadex,
the dosage of rocuronium should have been suffi-
cient to reverse sugammadex, however, it is diffi-
cult to predict the rate at which rocuronium was
degrading in this patient. As a result, unbound
sugammadex was likely able to inhibit the addi-
tional rocuronium and prevent neuromuscular block-
ade. In this case, train of four (TOF) monitoring was
not used. TOF monitoring would have assessed
neuromuscular block.
The concentration of rocuronium and the dura-
tion between the second rocuronium dose and
sugammadex are the major factors in achieving ade-
quate neuromuscular block. Animal studies have
shown that non-steroidal agents such as suxametho-
nium or cistracurium given immediately after the
use of sugammadex can produce variable degrees
of neuromuscular block (9). Suxamethonium is un-
affected by sugammadex and therefore would be
an appropriate drug when muscle relaxation is re-
quired (9,10). However, the required dosage of sux-
amethonium is not currently known after sugam-
madex. Other muscle relaxants like mivacrium and
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atracurium are also non-steroidal but are currently
not available in Japan.
In conclusion, when immediate surgery is nec-
essary following sugammadex administration, higher
doses of rocuronium are necessary in order to in-
duce neuromuscular blockade. Also, it is important
to use the smallest possible dose of sugammadex
to avoid difficult situation such a re-intubation or
re-surgery. Options might be limited when high
dose of sugammadex is administered. As in this
case, deep anesthesia via intravenous analgesics and
inhaled anesthetics can be utilized, but hypotension
and bradycardia must be monitored closely.
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